Immunological effects of BRAF+MEK inhibition

Paolo A. Ascierto, Reinhard Dummer

Research output: Contribution to journalReview articlepeer-review


Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.

Original languageEnglish
Article numbere1468955
Issue number9
Publication statusPublished - Sep 2 2018


  • advanced melanoma
  • BRAF
  • immune therapy
  • MEK
  • target therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Immunological effects of BRAF+MEK inhibition'. Together they form a unique fingerprint.

Cite this